BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.
- The IND-enabling cardio-pulmonary GLP studies have been completed, and the metabolism and genotoxicity GLP studies are to be initiated shortly.
- Dr. Ahmad Doroudian, CEO of BetterLife, commented, “We are very encouraged with FDA’s recent decision to grant breakthrough therapy designation to LSD for generalized anxiety disorder (GAD) patients.
- In simple words, we believe BETR-001 will deliver all the therapeutic benefits of LSD without its side effects.”
BetterLife issued a total of $1.168 million 10% convertible debentures (the “Convertible Debentures”). - $800,000 of the Convertible Debentures mature on March 27, 2026 and $368,000 mature on April 1, 2026.